← Back to Search

Vitamin Supplement

Group B for Vascular Stiffness (NRM Trial)

N/A

Waitlist Available

Led By Ryan Hurt, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to end of study at 12 weeks

Awards & highlights

NRM Trial Summary

"This trial aims to investigate how a nicotinamide riboside supplement can impact the heart health of healthy adults."

Who is the study for?

This trial is for healthy adults aged 40-60 who are not pregnant, nursing, or trying to conceive. Participants must understand and agree to the study's procedures without any chronic diseases, unstable medical conditions, severe obesity, or recent use of certain natural health products.Check my eligibility

What is being tested?

The trial is testing the effects of a supplement called Nicotinamide Riboside Malate on cardiovascular health in comparison with a placebo. The goal is to see if this supplement can improve vascular function in healthy individuals.See study design

What are the potential side effects?

While specific side effects are not listed for this trial, potential risks may include allergic reactions to ingredients in the supplement and possible unknown impacts on liver or kidney function.

NRM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to end of study at 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to end of study at 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of study at 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction of Endothelial stiffness

NRM Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Group BActive Control1 Intervention

1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks

Group II: Group AActive Control2 Interventions

830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks

Group III: Group CPlacebo Group1 Intervention

2 identical Placebo capsules twice a day for 12 weeks

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,221 Previous Clinical Trials

3,768,940 Total Patients Enrolled

Ryan Hurt, MDPrincipal InvestigatorMayo Clinic

Brent Bauer, MDPrincipal InvestigatorMayo Clinic

8 Previous Clinical Trials

429 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I meet the criteria to participate in this clinical investigation?

"Individuals aged between 40 and 60 years with vascular rigidity are eligible for participation in this study. Approximately 200 individuals will be accepted into the trial."

Answered by AI

Is the recruitment phase for this study still ongoing?

"As per the details available on clinicaltrials.gov, recruitment for this study is currently closed. The trial was originally posted on May 15th, 2024 and last updated on March 28th, 2024. While this specific research endeavor is not actively enrolling participants at present, it's worth noting that there are presently ten other studies seeking candidates for participation."

Answered by AI